The Food and Drug Administration released final guidance for developers of psychedelic drugs on July 14, updating its draft recommendations from 2023 to provide an initial framework for future regulatory action.
Jefferies said in a note to investors, “FDA’s final guidance on psychedelics suggests the agency remains receptive to helping sponsors succeed.” The announcement follows positive data from Compass Pathways and Definium Therapeutics, both considered frontrunners in the psychedelics space. The new version of the guidance also comes after President Donald Trump’s executive order earlier this year urging U.S. health agencies to allow an established path to approval for drugs such as psilocybin, MDMA, and ibogaine.
Much of the feedback received by the FDA after releasing its draft focused on clinical trial design—particularly how to distinguish a drug candidate's therapeutic mechanism from other factors associated with psychedelic effects. While not much has changed since the draft version three years ago, the latest iteration offers more flexibility for sponsors bringing psychedelic compounds forward. This includes flexibility in modeling abuse potential and measuring overall effectiveness.
According to the guidance, abuse potential studies may not be necessary when assessments have already been well-characterized through extensive clinical studies and robust epidemiological data. Sponsors are encouraged to contact the FDA if they believe sufficient existing data demonstrates that human abuse potential is already well-characterized. Placebo trials remain complicated due to noticeable drug effects; therefore, additional blinding mechanisms and durability tests are suggested.
H.C. Wainwright said in a Tuesday note that the final guidance “largely reaffirm[s] the existing framework while signaling a preference for blinded durability data.” The document also establishes criteria for imposing a clinical hold if there is risk of illness or injury, including requirements for supervision by trained healthcare providers following administration.
Compass Pathways is developing COMP360—a psilocybin-based therapy—for treatment-resistant depression and recently received an expedited Commissioner’s National Priority Voucher review following Trump’s executive order. New Phase 3 trial data last week showed quick and durable results supporting ongoing submission efforts. Definium Therapeutics’ LSD formulation also demonstrated “profound” efficacy in late-stage trials last month; CEO Rob Barrow said these results “bring us one step closer to potentially delivering a transformative new treatment option as we advance toward FDA submission.”
The FDA will hold a public hearing regarding therapeutic use of psychedelic drugs on September 14. Jefferies called both timing and intention behind this meeting “curious,” questioning whether it might replace future advisory committee meetings unless clinical data prove controversial—especially as COMP360 could be approved by year-end.
